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Abstract
Background: PN is a secreted cell adhesion protein critical for carcinogenesis. In breast cancer, it is overexpressed
compared to normal breast, and a few reports suggest that it has a potential role as a prognostic marker.
Methods: Tumour samples obtained at the time of mastectomy from 200 women followed for a median
time of 18.7 years (range 0.5–29.5 years) were investigated through IHC with a polyclonal anti-PN
antibody using tissue microarrays. Epithelial and stromal PN expression were scored independently
according to the percentage of coloured cells; the 60th percentile of PN epithelial expression,
corresponding to 1 %, and the median value of PN stromal expression, corresponding to 90 %, were
used as arbitrary cut-offs. The relationships between epithelial and stromal PN expression and clinical-
pathological features, tumour phenotype and the risk of mortality following surgery were analysed.
Appropriate statistics, including the Fine and Gray competing risk proportional hazard regression model,
were used.
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Results: The expression of PN in tumour epithelial cells was significantly lower than that which was observed in
stromal cells (p < 0.000). No specific association between epithelial or stromal PN expression and any of the clinical-
pathological parameters analysed was found as it was observed in respect to mortality when these variables were
analysed individually. However, when both variables were considered as a function of the other one, the expression of
PN in the stromal cells maintained a statistically significant predictive value with respect to both all causes and cancer-
specific mortality only in the presence of high epithelial expression levels. No significant differences in either all causes
or BCa-specific mortality rates were shown according to epithelial expression for tumours displaying higher stromal PN
expression rates. However, the trends were opposite for the higher stromal values and the patients with high epithelial
expression levels denoted the group with the worst prognosis, while higher epithelial values in patients with lower
stromal expression levels denoted the group with the best prognosis, suggesting that PN epithelial/stromal
interactions play a crucial role in breast carcinogenesis, most likely due to functional cross-talk between the two
compartments. On the basis of PN expression in both compartments, we defined 4 subgroups of patients with
different mortality rates with the group of patients characterized by positive epithelial and low stromal PN expression
cells showing the lowest mortality risk as opposed to the groups of patients identified by a high PN expression in both
cell compartments or those identified by a low or absent PN expression in both cell compartments showing the worst
mortality rates. The differences were highly statistically significant and were also retained after multiparametric analysis.
Competing risk analysis demonstrated that PN expression patterns characterizing each of previous groups are
specifically associated with cancer-specific mortality.
Conclusions: Although they require further validation through larger studies, our findings suggest that the patterns of
expression of PN in both compartments can allow for the development of IHC “signatures” that maintain a strong
independent predictive value of both all causes and, namely, of cancer-specific mortality.
Keywords: Human periostin protein, Breast neoplasms, Extracellular matrix proteins, Prognosis, Biomarkers
Background
In spite of the major achievements of mammography
screening and of multimodality treatments, BCa still rep-
resents the leading cause of cancer death among women
in western countries [1]. While for many years treatment
choices have been tailored to clinical-pathological features
[2], many studies have recently focused on individual gene
or protein candidates with a potential causative role in
breast carcinogenesis, in the hope of identifying novel
prognostic/predictive markers able to refine the informa-
tion provided by clinical-pathological features [3–7].
Many of the cell abnormalities identified in solid tu-
mours involve structural proteins. One such protein, PN,
is produced and secreted by fibroblasts as a component
of the ECM. This protein, which is involved in regulating
intercellular adhesion [8, 9], has been recently suggested
to play a relevant role in human carcinogenesis [10, 11],
either through the interaction with multiple cell-surface
receptors, most notably integrins [12, 13], or with the
PI3-K/Akt pathway and other pathways [14, 15]. The ac-
tivation of these pathways promotes cell survival, angio-
genesis, invasion, metastasis, and perhaps more
importantly, epithelial-mesenchymal transition of carcin-
oma cells [16, 17]. The overexpression of PN in cancer
stroma and/or epithelium is usually associated with the
most malignant phenotypes and/or with the poorest out-
comes [10, 11]. To the best of our knowledge, to date
only a few studies have investigated the clinical relevance
of PN expression in BCa [18–20]. A statistically signifi-
cant association between epithelial overexpression and
poor prognosis features has been reported in two studies
[18, 19] while a direct relationship between PN epithelial
expression and tumour stage was described in another
small study [20]. Indeed, none of the previous studies
has investigated the prognostic role of PN stromal ex-
pression in BCa, though PN stromal overexpression
was significantly associated with tumour aggressive-
ness and/or prognosis in other types of solid tumours,
including lung, prostate, kidney, pancreatic, colon and
ovarian cancers [10, 11].
Previous findings prompted us to conceive the present
study, which was originally aimed at further exploring
the prognostic value of PN expression in BCa patients.
Methods
Patient selection and ethical aspects
We selected a cohort of 200 patients who had a histolog-
ically confirmed diagnosis of BCa between January 1985
and November 1990; these patients were subsequently
followed up at our Institute. The cohort was selected
based on the availability of a corresponding serum sam-
ple drawn at the time of surgery and cryopreserved up
to processing. We aimed to evaluate the prognostic
value of serum levels of PN as well. The results of this
second part of the project form the object of a separate
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paper [21]. Patients’ demography is summarised in
Table 1.
This research project was approved by the Ethical
Committee of Regione Liguria, and the patients’ data
were managed according to the Italian Data Protection
Authority prescriptions (http://www.garanteprivacy.it).
IHC analysis
IHC evaluations were performed using 3-μm sections of
paraffin embedded TMAs. Using the Tissue–Tek Quick-
Ray TM, two 2.0 mm diameter cores of tumour tissue
were incorporated into a 10 × 6 (60 cores) TMA
recipient block. Four TMAs were constructed containing
two cores for each one of the 200 tumour blocks.
The PN (OSF-2) polyclonal rabbit antibody (Acris
Antibodies, Herford, Germany) suitable for the various
isoforms of PN was used at a dilution of 1:500. We used
this antibody in a previous study in prostate cancer [22].
TMA sections were immune stained using the Bench-
mark XT automatic stainer (Ventana Medical Systems,
SA Strasbourg, France). Slides were deparaffinized, and
after adding high pH, heat induced, standard citrate buf-
fer (30 min), the antibody-antigen complex was relieved
using the polymeric detection system (Ventana Medical
System Ultraview Universal DAB Detection Kit). A nega-
tive and a positive control were used for each staining
run. The negative control consisted of performing the
entire IHC procedure on adjacent sections in the ab-
sence of the primary antibody. Then, the sections were
counter-stained with Gill's modified haematoxylin,
cover-slipped and evaluated at 10×, 40× and 60× magni-
fications by two different observers (S.S & B.S.) using an
Olympus multi-headed light microscope. The entire area
of each tumour core was analysed.
To correlate PN expression to clinical pathological
variables, the tumour phenotype was re-assessed on the
same TMAs on the basis of the ER clone SP1, the PgR
clone 1E2, the Ki-67 clone 30–89 and the HER2 clone
4B5b expression; IHC protocols currently adopted in the
Histopathology Unit of our Institute (see Authors affili-
ation) and based on the use of the IHC detection system
Ultra View DAB Detection Kit (Roche Ventana Medical
System, Tucson, AZ, USA) were followed.
PN, ER, PgR, KI67 and HER2 Scoring
To score epithelial and stromal PN expression, we ini-
tially decided to use the scoring system IRS adopted in
the previously mentioned study in prostate cancer [22].
IRS is obtained by multiplying the intensity value of im-
mune coloration by the percentage of stained cells, and
the score is applied to both epithelial and stromal cells.
The intensity of staining is arbitrarily graded as: absent
(0), weak (1+), moderate (2+), and strong (3+) while the
percentage of stained cells is quantified as negative (0 %
of positive cells), 1+ (<10 % positive cells), 2+ (10–50 %
of positive cells), 3+ (51–80 % of positive cells), and 4+
(>80 % of positive cells). However, we realized that there
was still a certain inter-observer variation in scoring the
intensity of immune coloration and because a strong rela-
tionship was found between the staining intensity and the
number of coloured cells, both in the epithelial and in the
stromal compartment (Fig. 1), we decided that scoring PN
expression exclusively as a function of the percentage of
coloured cells might be easier and more reproducible.
For ER, PgR and Ki67 scoring, the nuclear staining was
evaluated through the percentage of nuclear neoplastic
Table 1 Main characteristic of study patients (N = 200)
No. of patients (%)
Age at surgery, years
Median (range) 58 (31–84)
Menopausal status
Pre-menopausal 63 (31.5)
Post- menopausal 137 (68.5)
Tumour size: cm in diameter
≤ 2 94 (47.0)





Poor (<10 % of stained cells) 42 (21.0)
Rich (≥10 % of stained cells) 158 (79.0)
PgR status
Poor (<10 % of stained cells) 86 (43.0)
Rich (≥10 % of stained cells) 114 (57.0)
Ki-67
Low (<14 % of stained cells) 91 (45.5)





Luminal A 64 (32.0)
Luminal B (HER2-neg) 85 (42.5)
Luminal B (HER2-pos) 9 (4.5)
HER2 positive (non luminal) 8 (4.0)




adefinition of intrinsic subtypes of breast cancer according to [23]
beither chemotherapy or endocrine therapy or both
Nuzzo et al. BMC Cancer  (2016) 16:95 Page 3 of 13
area on the total area analysed, using the image analyser
Leica QWin software connected to a light microscope
Leica DMLA and using a 40× magnification. A Ki-67 pro-
liferation index threshold of 14 % was used to distinguish
tumours with low (<14 %) or high (≥14 %) proliferative
fractions. Relative to steroid hormone receptor status, tu-
mours were defined as ER a/o PgR poor (no nuclear stain-
ing or nuclear staining up to 9 % of cells) or as ER a/o
PgR rich (nuclear staining equal to 10 % or more of cells).
For HER2, tumour cores were assessed using the anti-
HER2/neu (4B5) rabbit monoclonal primary antibody
(Roche Ventana Medical System, Tucson, AZ, USA) and,
as recommended, only HER2 3+ tumours were regarded
as positive; HER2 2+ tumours were regarded as positive
only if a FISH assay (Vysis LSI HER2/neu spectrum or-
ange/CEP 17 spectrum green probe, Abbott molecular,
Abbott Park, Illinois, USA) demonstrated HER2 gene
amplification. Based on the 4 variables, tumours were
grouped into five major phenotypes, including luminal A
and luminal B types (i.e., B-like HER2 negative and B-like
HER2 positive, respectively), HER2-like and triple negative
phenotypes [23].
Statistical analysis
The correlation between PN expression in the epithelial
or stromal cells and clinical-pathological variables
The t-test was applied to compare the mean values (SE)
of epithelial PN expression with stromal PN expression
values. The chi-square test was used to analyse the dis-
tribution of PN phenotypes within the different tumour
subgroups, constructed on categorical variables.
The correlation between either epithelial or stromal
PN expression and clinical-pathological variables was in-
vestigated with the Pearson test.
The correlation between PN expression at the epithelial/
stromal level with all causes and BCa-specific mortality
Mortality data were obtained by consulting the patients’
flow charts. Information about the women who were lost
to follow-up was obtained by consulting the local Mor-
tality Registry or the registry offices of the patients’ place
of residence. All events that occurred by the deadline of
December 31st, 2013 were recorded and causes of death
were reported.
Mortality curves were constructed through the cumu-
lative incidence function estimate by the Kaplan-Meier
method and compared using the log-rank test [24].
Stromal PN expression was first analysed in univariate
models utilizing the median percentages of immune
stained cells chosen as an arbitrary cut-off. The median
percentage value of stromal PN immune coloration was
90 %. Because the median percentage value of epithelial
PN immune coloration was 0 %, patients were broken
down according to the 60th percentile, which corresponded
to 1 %. The use of this cut-off in practice implied separat-
ing epithelial PN negative cells from epithelial PN positive
cells. Based on the expression rates of coloured epithelial
and stromal cells, 4 distinct PN tumour phenotypes could
be arbitrarily identified: 1) epithelial PN positive tumours
also expressing high PN stromal values (≥90 %), 2) epithe-
lial PN positive tumours expressing low PN stromal values
(i.e., <90 %), 3) epithelial PN negative tumours expressing
high PN stromal levels, and 4) epithelial negative PN tu-
mours expressing low PN stromal levels (Fig. 2). To evalu-
ate the independent role of PN expression in either
stromal or in epithelial tumour cells and that of the 4 phe-
notypes identified based both on epithelial and stromal ex-
pression rates, Cox proportional hazards models were
fitted to all causes and BCa-specific mortality data [25].
The cumulative incidence function was used to describe
Fig. 1 The correlation between the intensity of immunostaining and the percentage of stained cells in the tumour stromal (a) and epithelial
(b) compartments
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cause-specific mortality, and the Fine and Gray’s test was
used to investigate the cause-specific mortality differences
[26]. Mortality risks were expressed as HR estimates and
their 95 % confidence intervals CIs were also calculated.
All p values were two-tailed. The IBM software Statistical
Package for Social Sciences (SPSS) version 21.0 for Win-
dows (SPSS Inc. Chicago, Illinois, USA) and STATASE11
were used for data analysis.
Results
PN expression in the epithelial and stromal cells
Distinct stromal and epithelial staining characteristics
allowed for the evaluation of PN staining in the selected
TMAs. Both in epithelial and in stromal cells, PN was
expressed mainly in the cytoplasm, which showed a dif-
fuse granular tan coloration. Of the 200 tissue speci-
mens, 104 (52 %) displayed ≥80 %, 64 (32 %) 51–79 %,
and 29 (14.5 %) 10–50 % stromal cell PN staining while
only 3 specimens (1,5 %) showed no staining for PN in
cells. As previously mentioned, the median percentage
value of stromal cells expressing PN was 90 %. The ex-
pression of PN in tumour epithelial cells was signifi-
cantly lower than in stromal cells (p < 0.000). In fact, 120
(60 %) of the 200 tissue specimens showed no epithelial
PN staining at all; 34 (17 %) displayed 10–50 % and 38
out of 200 (23 %) showed 51–80 % coloured cells while
only 8 specimens showed ≥80 % coloured cells. Notably,
PN expression in stromal cells significantly correlated
with PN expression in epithelial cells (Pearson correl-
ation test: p < 0.000; data not shown).
The association between PN expression in epithelial and/
or stromal cells and clinical-pathological variables
No specific correlation of epithelial or stromal PN ex-
pression with any of the clinical-pathological variables
(age at surgery, menopausal status, tumour size, nodal
status, ER status, PgR status, proliferative activity, HER2
expression/amplification and tumour phenotype accord-
ing to the four variables) was found (Table 2). Accord-
ingly, no significant correlation of the 4 epithelial/
stromal PN phenotypes with clinical pathological vari-
ables was observed (data not shown).
The correlation between PN expression in epithelial and/
or stromal cells with all causes and BCa-specific mortality
At a median follow-up time of 18.7 years (range,0.5–
29.5), 126 deaths were recorded, of which 79 were BCa-
related. As previously mentioned, the correlation be-
tween PN expression with all causes and BCa-specific
mortality was explored in univariate models. As is
shown in Fig. 3a, b, c, and d, no correlation was found
when PN expression in stromal or epithelial cells was
analysed on an individual basis. However, as is shown in
Figs. 4a, b, c and d and 5a, b, c and d, there were distinct
Fig. 2 Tumour specimens corresponding to the 4 PN phenotypes identified based both on epithelial and stromal expression rates (see text).
Negative: 0 % of stained cells; positive: at least 1 % of stained cells; low: less than 90 % of stained cells; high: more or equal to 90 % of stained cells
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interactions between PN expression in the two compart-
ments and either all causes or BCa-specific mortality
when the two variables (i.e., epithelial or stromal expres-
sion) were analysed as one as a function of the other. In
fact, there were no substantial differences in all causes
or BCa-specific mortality rates according to PN stromal
expression as a function of epithelial expression for epi-
thelial negative tumours (Fig. 4a & b). In contrast, a
statistically significant association between stromal PN
expression and both all causes and BCa-specific mortal-
ity was observed for epithelial positive tumours (Fig. 4c
& d) even after adjusting comparisons by age, meno-
pausal status, tumour size, nodal status and adjuvant
systemic therapy, i.e., those variables listed in Table 1
showing to predict mortality in univariate models (data
not shown). The analysis of the correlation of PN
Table 2 Correlation between either epithelial or stromal PN expression and clinical-pathological variables
Epithelial Expression (% cells stained) Stromal Expression (% cells stained)
Negativea Positivea p= Lowa Higha p=
n = 120 n = 80 n = 99 n = 101
Median age at surgery, years
≤ 58 64 (53.3 %) 39 (48.8 %) 0.6 57 (57.6 %) 46 (45.5 %) 0.1
> 58 56 (46.7 %) 41 (51.2 %) 42 (42.4 %) 55 (54.5 %)
Menopausal status
Pre-menopausal 41 (34.2 %) 22 (27.5 %) 0.3 35 (35.4 %) 28 (27.7 %) 0.3
Post-menopausal 79 (65.8 %) 58 (72.5 %) 64 (64.6 %) 73 (72.3 %)
Tumour size: cm in diameter
≤ 2 61 (50.8 %) 33 (41.3 %) 0.2 51 (51.5 %) 43 (42.6 %) 0.2
> 2 59 (49.2 %) 47 (58.7 %) 48 (48.5 %) 58 (57.4 %)
Nodal status
Node-negative 60 (50.0 %) 45 (56.3 %) 0.4 50 (50.5 %) 55 (54.5 %) 0.6
Node-positive 60 (50.0 %) 35 (43.7 %) 49 (49.5 %) 46 (45.5 %)
ER status
Poor 29 (24.2 %) 13 (16.3 %) 0.2 23 (23.2 %) 19 (18.8 %) 0.4
Rich 91 (75.8 %) 67 (83.7 %) 76 (76.8 %) 82 (81.2 %)
PgR status
Poor 50 (41.7 %) 36 (45.0 %) 0.6 46 (46.5 %) 40 (39.6 %) 0.3
Rich 70 (58.3 %) 44 (55.0 %) 53 (53.5 %) 61 (60.4 %)
Ki-67
Low 53 (44.2 %) 38 (47.5 %) 0.6 44 (44.4 %) 47 (46.5 %) 0.7
High 67 (55.8 %) 42 (52.5 %) 55 (55.6 %) 54 (53.5 %)
HER2 status
Negative 110 (91.7 %) 73 (91.3 %) 0.9 88 (88.9 %) 95 (94.1 %) 0.2
Positive 10 (8.3 %) 7 (8.7 %) 11 (11.1 %) 6 (5.9 %)
Phenotypeb
Luminal A 39 (32.5 %) 25 (31.3 %) 0.6 29 (29.3 %) 35 (34.7 %) 0.7
Luminal B (HER2-neg) 47 (39.2 %) 38 (47.5 %) 41 (41.4 %) 44 (43.6 %)
Luminal B (HER2-pos) 5 (4.2 %) 4 (5.0 %) 6 (6.1 %) 3 (3.0 %)
HER2 positive (non luminal) 5 (4.2 %) 3 (3.7 %) 5 (5.1 %) 3 (3.0 %)
Triple negative 24 (20.0 %) 10 (12.5 %) 18 (18.2 %) 16 (15.8 %)
Adjuvant systemic therapyc
No 48 (40.0 %) 39 (48.8 %) 0.2 43 (43.4 %) 44 (43.6 %) 0.9
Yes 72 (60.0 %) 41 (51.2 %) 56 (56.6 %) 57 (56.4 %)
aNegative: 0 % of stained cells; positive: at least 1 % of stained cells; low: less than 90 % of stained cells; high: more or equal to 90 % of stained cells
bdefinition of intrinsic subtypes of breast cancer according to [23]
ceither chemotherapy or endocrine therapy or both
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epithelial expression as a function of stromal expression
with either all causes or BCa-specific mortality yielded
specular results. In fact, while no significant differences in
either all causes or BCa-specific mortality rates were
shown according to epithelial expression for tumours dis-
playing higher stromal PN expression rates (Fig. 5c & d), a
statistically significant difference favoured PN epithelial
positive tumours displaying lower PN stromal expression
levels (Figs. 5a & b), again after adjusting for age, meno-
pausal status, tumour size, nodal status and adjuvant sys-
temic therapy. Comparable trends emerged when the
mortality analysis was extended to the 4 PN epithelial/
stromal phenotypes previously identified. Figure 6a shows
that in fact the 4 groups have different probabilities of
dying, the best outcome favouring the patients with epi-
thelial positive and low stromal PN expression rates and
the worst outcome for patients with either epithelial posi-
tive and high stromal PN expression rates or epithelial
negative and low stromal expression rates. The results
relative to BCa-specific mortality were almost comparable
(Fig. 6b). In both cases, the comparisons were adjusted for
the covariates previously mentioned.
The association between each one of the 4 epithelial-
stromal PN phenotypes and mortality with respect to
Fig. 3 All causes (a and c) and BCa-specific mortality (b and d) of study patients as a function of epithelial and stromal PN expression. Epithelial
PN expression was analysed using the 60th percentile of immune stained cells, corresponding to 1 % as an arbitrary cut-off. Stromal PN expression
was analysed using the median percentage of immune stained cells, corresponding to 90 % as an arbitrary cut-off. All causes and BCa-specific mortality
comparisons were adjusted by age, menopausal status, tumour size, nodal status, and adjuvant systemic therapy: see text for further explanations.
Negative: 0 % of stained cells; positive: at least 1 % of stained cells; low: less than 90 % of stained cells; high: more or equal 90 % of stained cells. HR:
hazard ratio, 95 % CI: 95 % confidence interval
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the cause of death was further and more accurately in-
vestigated through competing risk analysis (Fig. 7a & b).
The curves show that PN phenotypes do not appear to
correlate with breast cancer unrelated deaths and, in
particular, that there is no difference at all relative to
BCa unrelated mortality between the phenotype with a
better prognosis and those showing the poorest out-
comes. In contrast, a statistically significant correlation
of PN epithelial/stromal phenotypes with BCa-specific
mortality was observed; in particular, a strict relationship
between the PN phenotype and increasing probability of
death was observed. In fact, the lowest probability was
observed for the women characterized by the most
favourable phenotype (epithelial positive, low stromal ex-
pression) while the highest probabilities were observed
for the women characterized by the less favourable PN
phenotypes (epithelial negative, low stromal expression;
epithelial positive, high stromal expression).
Discussion
PN expression in the epithelial and stromal cells
We have shown that PN is mostly expressed by stromal
cells where it appears to be localized mainly in the cyto-
plasm. In fact, of the 200 tissue specimens included into
our cohort, 104 (52 %) displayed ≥80 %, 64 (32 %) 51–79 %,
and 29 (14.5 %) 10–50 % stromal cell PN staining while
Fig. 4 All causes (a and c) and BCa-specific mortality (b and d) of study patients according to PN epithelial expression as a function of stromal PN
expression. Epithelial PN expression was analysed using the 60th percentile of immune stained cells, corresponding to 1 % as an arbitrary
cut-off. Stromal PN expression was analysed using the median percentage of immune stained cells, corresponding to 90 % as an arbitrary
cut-off. All causes mortality and BCa-specific mortality comparisons were adjusted by age, menopausal status, tumour size, nodal status,
and adjuvant systemic therapy: see text for further explanations. Negative: 0 % of stained cells; positive: at least 1 % of stained cells; low:
less than 90 % of stained cells; high: more or equal 90 % of stained cells. H: hazard ratio, 95 % CI: 95 % confidence interval
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only 3 specimens (1,5 %) showed no staining for PN in
cells. This finding is an obvious consequence of the fact
that PN is one of the major components of the ECM and is
consistent with previous observations by us and other in-
vestigators in the great majority of solid tumours [10, 11].
A prevalent expression of PN in the stroma of tissue sam-
ples selected for previously mentioned studies in BCa was
also reported; however, neither Puglisi’s group [18] nor the
Chinese group [19] provide detailed information about
PN stromal expression and both studies, as already men-
tioned before, do not take into account stromal expression
in their attempt to correlate PN expression with clinical
pathological variables or clinical outcome. No adequate
information on PN expression and localization is provided
by Zhang et al. [20]. We also found that PN is expressed
in 40 % of epithelial cells. Our data are comparable with
those reported by Puglisi et al. [18], who observed epithe-
lial staining in 57 % of epithelial cells, and those reported
by Xu et al. [19], who showed PN epithelial staining in
30 % of cells. Taken together, our findings and those re-
ported in the literature confirm that in BCa tissues PN is
mostly and highly expressed in stromal cells but that the
protein is also expressed in 30–60 % of epithelial tumour
cells and that, in both cell compartments, it appears to
localize mainly in the cytoplasm [18, 19]. These findings,
consistent with previous observations in other solid tu-
mours [10, 11], corroborate the assumption that PN might
play a major role in carcinogenesis.
Fig. 5 All causes (a and c) and BCa-specific mortality (b and d) of study patients according to PN stromal expression as a function of epithelial PN
expression. Epithelial PN expression was analysed using the 60th percentile of immune stained cells, corresponding to 1 % as an arbitrary
cut-off. Stromal PN expression was analysed using the median percentage of immune stained cells, corresponding to 90 % as an arbitrary
cut-off. All causes and BCa-specific mortality comparisons were adjusted by age, menopausal status, tumour size, nodal status, and adjuvant systemic
therapy: see text for further explanations. Negative: 0 % of stained cells; positive: at least 1 % of stained cells; low: less than 90 % of stained cells; high:
more or equal 90 % of stained cells. HR: hazard ratio, 95 % CI: 95 % confidence interval
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The correlation between PN expression with clinical-
pathological variables
As previously reported in the results session, no specific
correlation between either epithelial or stromal PN ex-
pression with any of the clinical-pathological variables
considered by us (age at surgery, menopausal status,
tumour size, nodal status, ER status, PgR status, HER2
expression/amplification, proliferative activity, tumour
phenotype defined on the basis of the last 4 variables)
was found (Table 2). Accordingly, no correlation with
clinical pathological variables was found after grouping
tumour samples based on the actual pattern of epithe-
lial/stromal expression (data not shown). As previously
mentioned, neither Puglisi’s [18] nor Xu’s group [19]
analysed the putative correlation of PN expression in
stromal cells with clinical pathological variables, though
both groups showed that high PN expression was com-
monly found in tumour stroma; however, they only con-
sidered epithelial expression for their analysis. This fact,
in our opinion, might represent a major limitation of
their studies. There is in fact mounting evidence that
epithelial/stromal interactions are likely crucial for the
role played by PN in tumour progression through a type
of functional cross-talk between the two compartments
[21, 27–29]. Beyond previous considerations, we can
only compare our results and those of the above
Fig. 6 All causes (a) and BCa-specific mortality (b) of study patients according to the four distinct PN tumour phenotypes identified on the basis
of both epithelial and stromal PN expression. Epithelial PN expression was analysed using the 60th percentile of immune stained cells, corresponding
to 1 % as an arbitrary cut-off. Stromal PN expression was analysed using the median percentage of immune stained cells, corresponding to 90 % as an
arbitrary cut-off. All causes and BCa-specific mortality comparisons were adjusted by age, menopausal status, tumour size, nodal status, and adjuvant
systemic therapy: see text for further explanations. Negative: 0 % of stained cells; positive: at least 1 % of stained cells; low: less than 90 % of stained
cells; high: more or equal 90 % of stained cells. HR: hazard ratio, 95 % CI: 95 % confidence interval
Fig. 7 Cumulative incidence of death at 30 years from surgery according to both epithelial and stromal PN expression (a: Breast cancer related
deaths; b: Breast cancer unrelated deaths) Epithelial PN expression was analysed using the 60th percentile of immune stained cells, corresponding
to 1 % as an arbitrary cut-off. Stromal PN expression was analysed using the median percentage of immune stained cells, corresponding to 90 %
as an arbitrary cut-off. Cumulative incidence of death comparisons were adjusted by age, menopausal status, tumour size, nodal status, and adjuvant
systemic therapy: see text for further explanations. Negative: 0 % of stained cells; positive: at least 1 % of stained cells; low: less than 90 % of stained
cells; high: more or equal 90 % of stained cells. HR: hazard ratio, 95 % CI: 95 % confidence interval
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mentioned studies with respect to PN expression in the
epithelial cells. Puglisi et al. [18] found a significant asso-
ciation between PN cytoplasmic epithelial expression
and tumour size, PgR status, VEGF-A and VEGFR-1,
and a significant association of nuclear PN expression
and tumour size, ER and PgR status, VEGF-A, VEGFR-1
and VEGFR-2. To our knowledge, these investigators are
the only ones to demonstrate the nuclear expression of
the protein in epithelial cells and this further compli-
cates the comparison of their findings with our own and
those reported by the other investigators. Puglisi’s find-
ings are not consistent with the lack of any correlation
between epithelial PN expression and the clinical-
pathological findings observed in our study, though we
did not include variables such as VEGF and its receptors
[18]. We do not have an explanation for this fact; how-
ever, though both studies included comparable numbers
of patients and the percentages of coloured cells was
also comparable, in our study we have taken into ac-
count the percentage of coloured cells rather than the
staining intensity as was done by Puglisi and co-workers
[20]. Our findings also do not fit with those reported by
Xu et al. [19], as in our study, epithelial PN positivity
per se was not associated with any of the clinical patho-
logical variables. Again, it is not possible to provide an
explanation for the differences observed. However, it
may not be trivial to underline the aspects that differen-
tiate the two cohorts on study. In fact, the Chinese co-
hort was much larger than our own; moreover, there
were significant differences in tumour stage at diagnosis
(approximately 26 % of Chinese patients had distant me-
tastases at diagnosis) and tumour phenotype (in particu-
lar, unusual rates of HER2 positive and triple negative
tumours were recorded among Chinese patients). Gen-
etic and epigenetic differences that can provide an ex-
planation for the phenotypic differences between our
cohort and the Chinese cohort might play a role in
explaining the different correlation of PN epithelial ex-
pression with tumour phenotype in the two cohorts.
Zhang et al. [20] described only a trend for PN expres-
sion to increase from stage I to stage IV tumours; how-
ever, they do not report on the putative correlation of
PN expression with any clinical pathological variable,
thus rendering it impossible to compare our findings
with their own.
The correlation of PN expression with all causes and BCa-
specific mortality
As previously mentioned, Puglisi et al. [18] did not ana-
lyse clinical outcome according to PN expression, while
Zhang et al. [20] observed that PN expression was corre-
lated with tumour stage at diagnosis. Only Xu’s study
has previously evaluated the correlation of PN epithelial
expression and BCa-specific mortality, showing that high
epithelial PN expression was significantly associated with
a higher mortality risk. In our study, a strong correlation
between positive epithelial PN expression and both all
causes and BCa-specific mortality was also found but only
in patients also characterized by a low stromal expression
of the protein (Figs. 4, 5 and 6). The trends shown in Fig. 6a
& b were confirmed by competitive risks analysis. This
analysis demonstrated a strong correlation of each PN epi-
thelial/stromal PN phenotype with BCa-related deaths,
suggesting a specific role for PN expression and interaction
according to its compartmentalization in affecting BCa le-
thality. The lack of any association of PN expression with
clinical pathological variables and the maintenance of sta-
tistically significant trends observed after adjusting for the
co-variates predictive in univariate models confirm the in-
dependent prognostic value of PN staining and suggest
that different biological mechanisms than those merely
correlated with the clinical pathological features at diagno-
sis might play a more crucial role in the later phases of the
natural history of the disease. In a BCa murine model,
Malanchi et al. [27] demonstrated that stromal PN is cru-
cial for metastatic colonisation through the interaction
with epithelial stem cells (which were also found by these
investigators to overexpress PN) at the metastatic niche
level. Tumour cells may stimulate or send a signal to the
surrounding tissues to produce PN at the ECM level. A re-
turn signal may also exist. These biological premises might
help in interpreting the results of our study where no
strong association between either epithelial or stromal PN
expression and mortality was observed when these vari-
ables were analysed on an individual basis while a signifi-
cant association between mortality and different epithelial/
stromal PN expression patterns was found. The possibility
of defining groups with hugely different outcomes on the
basis of the pattern of PN expression in both the epithelial
and stromal compartments was already demonstrated by
our group in prostate cancer [22]. Here again we were able
to demonstrate that stromal expression could display dif-
ferent prognostic implications in the patients depending
on protein epithelial expression [22]. In our previous study
on prostate cancer, the type of interaction between epithe-
lial and stromal PN expression appears to differ from that
observed in the present study. However, again we should
take into adequate account that different criteria have been
used to categorize PN expression in the two studies (IRS,
i.e., a score obtained by multiplying the percentage of
coloured cells by the degree of staining intensity in the
study on prostate cancer and the percentage of coloured
cells in the present study) and, above all, that the intrinsic
biologic differences correlated with tumour type might not
allow for the comparison of the results achieved in the two
studies. In fact, it is well known that different PN isoforms
are expressed by different tumours and are most likely in-
volved in carcinogenetic processes [30, 31], though, to our
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knowledge, information about PN isoforms specifically in-
volved in prostate or breast cancer is currently unknown.
Clearly, our findings should be regarded as merely explora-
tory and, as such, they should be taken with caution be-
cause they might present several limitations related to the
retrospective nature of our study and methodological is-
sues. This was, in fact, a retrospective cohort study per-
formed on a relatively small patient cohort. Both
conditions might represent a bias and affect the statistical
power of the study as well as the possibility to perform ap-
propriate sub-group comparisons. Moreover, our women
may not represent the current average population of
women newly diagnosed with BCa [32], and therapeutic
standards and attitudes have also been changing over time.
In fact, our patient cohort was referred to us between 1985
and 1990 and, therefore, show a relatively high (approxi-
mately 50 %) prevalence of women with tumours >2 cm in
size a/o with nodal involvement. For this reason, transfer-
ring our findings to current clinical situations might also
be difficult. The differences in patient populations and fol-
low up duration might also render it difficult to compare
our findings with the few ones previously reported in the
literature [18, 19]. Other aspects that might bias the com-
parison of our findings with those previously reported in
the literature are likely to be related to methodological is-
sues. While the same polyclonal rabbit antibody was used
in our study and in those by Puglisi et al. [18] and by Xu
et al. [19], a different scoring method was used by Puglisi’s
group based exclusively on the intensity of coloration.
Though we have demonstrated a direct relationship be-
tween staining intensity and the percentage of coloured
cells (Fig. 1), there is no doubt that determining staining in-
tensity is much more subject to individual interpretation,
especially in the absence of referee standards. However, our
choice to score PN expression only on the basis of the per-
centage of coloured cells might be questioned, and indeed
it might not represent the most appropriate scoring
method, especially relative to stromal cells. In fact, we
realize that it might not always be easy to distinguish be-
tween specific staining of the cellular component of the
stroma from the non-specific staining of PN that accumu-
lates in the extracellular matrix. The PN expression at the
cellular level in the stroma might not be appropriate even
from the biological point of view because the PN se-
creted in the extracellular matrix is not “biologically
inert” but rather contributes to the functional role of
the protein. While it is intuitive that the expression
of PN in the extracellular matrix can be “quantified”
only on the basis of staining intensity, it might be re-
assuring that the coefficient of correlation between
the percentage of coloured cells in the stroma and
the intensity of immune staining did not change when
the intensity of the immune staining was recalculated
on the basis of the intensity observed both in the
cellular and in the extracellular component of the
stroma (c:0.97; p < 0.000).
Conclusions
In conclusion, we demonstrated that PN is expressed
mainly in tumour stromal cells compared to epithelial cells
and that PN expression in both compartments appears to
be a biological requirement to define different prognostic
subgroups of BCa. Multiparametric analysis confirms that
PN expression has an independent prognostic value with
respect to the clinical-pathological variables that are com-
monly used to define patient prognosis. The prognostic
role of PN expression and compartmentalization appears
to be specific for BCa-related mortality and is maintained
up to 30 years after breast surgery. The identification of
the specific isoforms involved in breast cancer might be of
great help, not only to better elucidate the mechanisms in-
volved in the compartmental interactions, which are
thought to be crucial in driving tumour progression, but
also to increase the prognostic and predictive accuracy of
PN staining. As previously stated, our findings should be
regarded as merely exploratory and, as such, they should
be taken with caution. Nonetheless, they warrant IHC
methodological standardization and further validation of
the potential usefulness of PN as a prognostic marker in
BCa through larger prospective studies should be
investigated.
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